Cervilenz Inc. is pleased to announce presentation of new data from an independent study at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in San Francisco on February 15th.
Two new studies demonstrating the clinical utility of the CerviLenz® device were presented today at the 10th World Congress of Maternal and Neonatal Health in Rome, Italy.
Interplex Medical, LLC, an FDA-registered, ISO 13485-certified company that designs and manufactures medical products for OEM customers, will display a variety of newly developed components, subsystems and finished products at MEDICA 2011, including an innovative device it helped develop for Cleveland-based Cervilenz Inc.
Cervilenz Inc. will be presenting this year at AdvaMed 2011 in Washington, DC. to share news on a significant advance in obstetrics and how their new device will help physicians improve pregnancy outcomes.
Cervilenz Inc. announced today the addition of a new member to its Board of Directors. Eileen Maus brings 20 years of experience in the life sciences industry as a senior sales and marketing executive.
Cervilenz Inc. has been selected to present at OneMedForum, a prestigious conference which connects healthcare/life science-focused emerging companies, business development executives, and investors.
Cervilenz Inc. has been selected to present the company's background, progress and future plans at OneMedForum 2011 in San Francisco, CA. The presentation will take place on Tuesday, January 11, 2011 at 4:10 pm PST at the Sir Francis Drake Hotel.
In November, the Journal of Maternal-Fetal and Neonatal Medicine published the results of a study conducted by Richard Burwick, MD at Harbor-UCLA Hospital in Los Angeles, CA, examining the utility of CerviLenz in predicting preterm birth in women with symptoms of preterm labor.
Satisfied Users & 
Approved Press Releases
